Ensign Peak Advisors Inc Decreases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ensign Peak Advisors Inc trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 41,649 shares of the biopharmaceutical company’s stock after selling 1,093 shares during the period. Ensign Peak Advisors Inc’s holdings in Regeneron Pharmaceuticals were worth $29,668,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. OFI Invest Asset Management purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $28,000. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 15 shares in the last quarter. Avalon Trust Co purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $36,000. Crowley Wealth Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $36,000. Finally, Private Wealth Management Group LLC increased its position in Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 39 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $527.78 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $520.50 and a twelve month high of $1,211.20. The company has a market capitalization of $57.70 billion, a PE ratio of 13.79, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a fifty day simple moving average of $613.08 and a 200-day simple moving average of $695.07.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analysts’ expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue was down 3.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $9.55 earnings per share. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.96%.

Analyst Ratings Changes

A number of research firms have issued reports on REGN. Guggenheim reduced their target price on shares of Regeneron Pharmaceuticals from $940.00 to $810.00 and set a “buy” rating on the stock in a report on Thursday, May 1st. Royal Bank of Canada decreased their target price on shares of Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 30th. UBS Group reduced their price target on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 30th. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 22nd. Finally, Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $695.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating, eighteen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $892.60.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.